Vireo Growth (VREOF) Other Non-Current Liabilities (2021 - 2026)

Vireo Growth (VREOF) reported Other Non-Current Liabilities of $30.0 million for Q1 2026, up 80376.42% on a YoY basis from N/an in Q1 2025, and up 1400.0% sequentially from $2.0 million in Q4 2025.

Vireo Growth (VREOF) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 6 years of Other Non-Current Liabilities data on file, last reported at $30.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Liabilities rose 80376.42% year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (up 80376.42% YoY), and the FY2025 full-year result was $2.0 million, changed N/A from the prior year.
  • Other Non-Current Liabilities climbed to $30.0 million in Q1 2026, from $2.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $30.0 million in Q1 2026 to a low of $1613.0 in Q4 2022.
  • A 5-year average of $4.1 million and a median of $216938.0 in 2024 frame the typical range for Other Non-Current Liabilities.
  • Across the five-year window, Other Non-Current Liabilities declined 8.66% in 2024 and surged 80376.42% in 2026, its largest moves.
  • Tracing VREOF's Other Non-Current Liabilities over 5 years: stood at $1613.0 in 2022, then jumped by 7454.0% to $121846.0 in 2023, then soared by 78.04% to $216938.0 in 2024, then surged by 821.92% to $2.0 million in 2025, then surged by 1400.0% to $30.0 million in 2026.
  • Business Quant data shows VREOF's Other Non-Current Liabilities at $30.0 million in Q1 2026, $2.0 million in Q4 2025, and $1.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 30.00 Mn
Dec 31, 2025 2.00 Mn
Sep 30, 2025 1.10 Mn
Jun 30, 2025 10.63 Mn
Mar 31, 2025 37,278.00
Sep 30, 2024 216,938.00
Jun 30, 2024 196,598.00
Dec 31, 2023 121,846.00
Sep 30, 2023 235,577.00
Jun 30, 2023 215,237.00
Dec 31, 2022 1,613.00
Sep 30, 2021 3.08 Mn
Jun 30, 2021 3.71 Mn
Mar 31, 2021 5.24 Mn